Where is VBIO stock listed?

Valion Bio, Inc. trades under the ticker VBIO on NASDAQ.

How can I research VBIO's financials and filings?

Vantafin provides Valion Bio, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the VBIO profile.

Valion Bio, Inc. (VBIO) stock profile

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Key facts

Symbol	VBIO
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CEO	Michael R. Cavanaugh
Employees	52
Headquarters	San Antonio, TX, US
IPO	2021-11-11
Website	valionbio.com

Explore VBIO on Vantafin

Frequently asked questions

What does Valion Bio, Inc. (VBIO) do?: Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Where is VBIO stock listed?: Valion Bio, Inc. trades under the ticker VBIO on NASDAQ.
How can I research VBIO's financials and filings?: Vantafin provides Valion Bio, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the VBIO profile.

Valion Bio, Inc. (VBIO) stock profile

Key facts

Symbol	VBIO
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CEO	Michael R. Cavanaugh
Employees	52
Headquarters	San Antonio, TX, US
IPO	2021-11-11
Website	valionbio.com

Explore VBIO on Vantafin

Frequently asked questions

What does Valion Bio, Inc. (VBIO) do?: Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Where is VBIO stock listed?: Valion Bio, Inc. trades under the ticker VBIO on NASDAQ.
How can I research VBIO's financials and filings?: Vantafin provides Valion Bio, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the VBIO profile.